Glabellar lines - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Glabellar lines - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Glabellar lines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glabellar lines: Overview
Glabellar lines or glabella lines appear in the glabella, the skin over the forehead, between and above the eyebrows and right above the nose. When a person wrinkle his/her face by talking, yawning, laughing, or making expressions, the glabella is the skin most affected by the muscle activity beneath the surface. Over time, as a result of a combination of causes including genetics, skin tightness, muscle activity, face shape, and various intrinsic and extrinsic causes, the lines that appear in your glabella may remain permanently, evolving into wavy furrows in the forehead. These are known as glabellar lines and they can continuously worsen over time if not treated.
'Glabellar lines - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glabellar lines pipeline landscape is provided which includes the disease overview and Glabellar lines treatment guidelines. The assessment part of the report embraces, in depth Glabellar lines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glabellar lines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Glabellar lines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glabellar lines Emerging Drugs
Further product details are provided in the report..
Glabellar lines: Therapeutic Assessment
This segment of the report provides insights about the different Glabellar lines drugs segregated based on following parameters that define the scope of the report, such as:
Glabellar lines: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glabellar lines therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glabellar lines drugs.
Glabellar lines Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Glabellar lines - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Glabellar lines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glabellar lines: Overview
Glabellar lines or glabella lines appear in the glabella, the skin over the forehead, between and above the eyebrows and right above the nose. When a person wrinkle his/her face by talking, yawning, laughing, or making expressions, the glabella is the skin most affected by the muscle activity beneath the surface. Over time, as a result of a combination of causes including genetics, skin tightness, muscle activity, face shape, and various intrinsic and extrinsic causes, the lines that appear in your glabella may remain permanently, evolving into wavy furrows in the forehead. These are known as glabellar lines and they can continuously worsen over time if not treated.
'Glabellar lines - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glabellar lines pipeline landscape is provided which includes the disease overview and Glabellar lines treatment guidelines. The assessment part of the report embraces, in depth Glabellar lines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glabellar lines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glabellar lines R&D. The therapies under development are focused on novel approaches to treat/improve Glabellar lines.
This segment of the Glabellar lines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glabellar lines Emerging Drugs
- ATGC-100: EuBiologics
- DaxibotulinumtoxinA for Injection (DAXI): Revance Therapeutics
Further product details are provided in the report..
Glabellar lines: Therapeutic Assessment
This segment of the report provides insights about the different Glabellar lines drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Glabellar lines
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Glabellar lines: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glabellar lines therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glabellar lines drugs.
Glabellar lines Report Insights
- Glabellar lines Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Glabellar lines drugs?
- How many Glabellar lines drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glabellar lines?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glabellar lines therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glabellar lines and their status?
- What are the key designations that have been granted to the emerging drugs?
- ATGC Biotech
- EuBiologics
- Ipsen
- Bonti
- Eirion Therapeutics
- Roche
- Galderma
- ATGC-100
- Daxibotulinumtoxin A
- IPN-10200
- EB-001
- AI-09
- RelabotulinumtoxinA
Introduction
Executive Summary
Glabellar lines: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glabellar lines – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glabellar lines companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glabellar lines Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DaxibotulinumtoxinA for Injection (DAXI): Revance Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
EB-001: Bonti
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
IPN-10200: Ipsen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
AI-09: Eirion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Glabellar lines Key Companies
Glabellar lines Key Products
Glabellar lines- Unmet Needs
Glabellar lines- Market Drivers and Barriers
Glabellar lines- Future Perspectives and Conclusion
Glabellar lines Analyst Views
Glabellar lines Key Companies
Appendix
Executive Summary
Glabellar lines: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glabellar lines – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glabellar lines companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glabellar lines Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DaxibotulinumtoxinA for Injection (DAXI): Revance Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
EB-001: Bonti
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
IPN-10200: Ipsen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
AI-09: Eirion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Glabellar lines Key Companies
Glabellar lines Key Products
Glabellar lines- Unmet Needs
Glabellar lines- Market Drivers and Barriers
Glabellar lines- Future Perspectives and Conclusion
Glabellar lines Analyst Views
Glabellar lines Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Glabellar lines
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Glabellar lines
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Glabellar lines
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Glabellar lines
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
